ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 923

Retinoic Acid Inhibits Expression of Interleukin 9 By Altering Enhancer Architecture

Daniella Schwartz1, Francoise Meylan2, Hong-Wei Sun3, Han-Yu Shih4, Kan Jiang4, Franziska Petermann4, Richard M. Siegel5, Arian Laurence6 and John J O'Shea7, 1NIAMS - Rheumatology, National Institutes of Health, Bethesda, MD, 2NIAMS, NIH, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4NIAMS, Rheumatology, National Institutes of Health, Bethesda, MD, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 6University of Oxford, Oxford, United Kingdom, 7NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: cytokines, epigenetics and interleukins (IL)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Vitamin A and its major metabolite, retinoic acid (ATRA), modulate T cell function and fitness to shape immune responses. Vitamin A deficiency causes increased susceptibility to infection, leading to the death of an estimated 250,000-600,000 children per year. Osteoarthritis has been linked to variants in the ALDH1A2 gene, which metabolizes Vitamin A to ATRA. Retinoic acid is an essential positive regulator of T effector cell responses, yet retinoids can also dampen immune responses through inhibition of effector cytokine production. Moreover, ATRA induces expression of the transcription factor Foxp3, which is necessary for immune tolerance. This multifaceted effect of ATRA complicates dissection of the molecular mechanisms that elicit negative immunoregulatory functions.

Methods: We aimed to evaluate the direct effects of retinoic acid induced immunomodulation that are not dependent on enhancing T regulatory cell function. We performed RNA-seq and compared the transcriptomes of ATRA-treated and untreated T helper cell subsets. We used Chromatin Immunoprecipitation-sequencing (ChIP-seq) and Assay for Transposase-Accessible Chromatin-sequencing (ATAC-seq) to characterize ATRA-induced changes in chromatin architecture.

Results: We characterized an ATRA-regulated gene signature that was independent of CD4 T cell subset. We identified IL-9 as the cytokine whose gene expression is most strongly inhibited. Using Foxp3-mutant (Scurfy) mice, we demonstrated that ATRA’s immunomodulatory effects, including IL-9 inhibition, are Foxp3-independent. We confirmed that retinoic acid potently inhibits IL-9 in T cells in vitro, and in T cells and Type 2 innate lymphoid cells (ILC2s) in an in vivo model of allergic lung disease. We mapped chromatin accessibility of the Il9 locus by ATAC-seq and enhancer marks by ChIP-seq, which led us to identify several novel Il9 enhancers. We observed that RAR-alpha binds directly to the Il9 locus, reduces chromatin accessibility, and disrupts looping between the Il9 promoter and associated enhancers.

Conclusion: Our observation suggests that ATRA-RAR-alpha directly suppresses IL-9 by modifying enhancer architecture, which may serve as a paradigm for the mechanism by which retinoic acid modulates cytokine expression.


Disclosure: D. Schwartz, None; F. Meylan, None; H. W. Sun, None; H. Y. Shih, None; K. Jiang, None; F. Petermann, None; R. M. Siegel, None; A. Laurence, None; J. J. O'Shea, None.

To cite this abstract in AMA style:

Schwartz D, Meylan F, Sun HW, Shih HY, Jiang K, Petermann F, Siegel RM, Laurence A, O'Shea JJ. Retinoic Acid Inhibits Expression of Interleukin 9 By Altering Enhancer Architecture [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/retinoic-acid-inhibits-expression-of-interleukin-9-by-altering-enhancer-architecture/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/retinoic-acid-inhibits-expression-of-interleukin-9-by-altering-enhancer-architecture/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology